IDEAS home Printed from https://ideas.repec.org/a/nat/nature/v615y2023i7950d10.1038_s41586-023-05704-6.html
   My bibliography  Save this article

Targeting TBK1 to overcome resistance to cancer immunotherapy

Author

Listed:
  • Yi Sun

    (Massachusetts General Hospital, Harvard Medical School)

  • Or-yam Revach

    (Massachusetts General Hospital, Harvard Medical School)

  • Seth Anderson

    (Broad Institute of MIT and Harvard)

  • Emily A. Kessler

    (Broad Institute of MIT and Harvard)

  • Clara H. Wolfe

    (Broad Institute of MIT and Harvard)

  • Anne Jenney

    (Harvard Medical School)

  • Caitlin E. Mills

    (Harvard Medical School)

  • Emily J. Robitschek

    (Broad Institute of MIT and Harvard)

  • Thomas G. R. Davis

    (Broad Institute of MIT and Harvard)

  • Sarah Kim

    (Broad Institute of MIT and Harvard)

  • Amina Fu

    (Massachusetts General Hospital, Harvard Medical School)

  • Xiang Ma

    (Massachusetts General Hospital, Harvard Medical School)

  • Jia Gwee

    (Massachusetts General Hospital, Harvard Medical School)

  • Payal Tiwari

    (Broad Institute of MIT and Harvard)

  • Peter P. Du

    (Broad Institute of MIT and Harvard)

  • Princy Sindurakar

    (Massachusetts General Hospital, Harvard Medical School)

  • Jun Tian

    (Massachusetts General Hospital, Harvard Medical School)

  • Arnav Mehta

    (Massachusetts General Hospital, Harvard Medical School
    Broad Institute of MIT and Harvard
    Dana-Farber Cancer Institute)

  • Alexis M. Schneider

    (Broad Institute of MIT and Harvard
    Massachusetts Institute of Technology)

  • Keren Yizhak

    (Technion)

  • Moshe Sade-Feldman

    (Massachusetts General Hospital, Harvard Medical School
    Broad Institute of MIT and Harvard)

  • Thomas LaSalle

    (Massachusetts General Hospital, Harvard Medical School)

  • Tatyana Sharova

    (Massachusetts General Hospital Cancer Center, Harvard Medical School)

  • Hongyan Xie

    (Massachusetts General Hospital, Harvard Medical School)

  • Shuming Liu

    (Harvard Medical School)

  • William A. Michaud

    (Massachusetts General Hospital Cancer Center, Harvard Medical School)

  • Rodrigo Saad-Beretta

    (Massachusetts General Hospital, Harvard Medical School)

  • Kathleen B. Yates

    (Massachusetts General Hospital, Harvard Medical School
    Broad Institute of MIT and Harvard)

  • Arvin Iracheta-Vellve

    (Broad Institute of MIT and Harvard)

  • Johan K. E. Spetz

    (Harvard Medical School
    Harvard School of Public Health
    Harvard School of Public Health)

  • Xingping Qin

    (Harvard Medical School
    Harvard School of Public Health
    Harvard School of Public Health)

  • Kristopher A. Sarosiek

    (Harvard Medical School
    Harvard School of Public Health
    Harvard School of Public Health)

  • Gao Zhang

    (The Wistar Institute
    Duke University School of Medicine
    Duke University School of Medicine)

  • Jong Wook Kim

    (UC San Diego
    UC San Diego
    UC San Diego)

  • Mack Y. Su

    (Massachusetts General Hospital and Harvard Medical School)

  • Angelina M. Cicerchia

    (Massachusetts General Hospital, Harvard Medical School)

  • Martin Q. Rasmussen

    (Massachusetts General Hospital, Harvard Medical School)

  • Samuel J. Klempner

    (Massachusetts General Hospital, Harvard Medical School)

  • Dejan Juric

    (Massachusetts General Hospital, Harvard Medical School)

  • Sara I. Pai

    (Massachusetts General Hospital Cancer Center, Harvard Medical School
    Massachusetts General Hospital)

  • David M. Miller

    (Massachusetts General Hospital, Harvard Medical School
    Massachusetts General Hospital and Harvard Medical School)

  • Anita Giobbie-Hurder

    (Dana-Farber Cancer Institute)

  • Jonathan H. Chen

    (Massachusetts General Hospital, Harvard Medical School
    Broad Institute of MIT and Harvard
    Massachusetts General Hospital)

  • Karin Pelka

    (Massachusetts General Hospital, Harvard Medical School
    Broad Institute of MIT and Harvard)

  • Dennie T. Frederick

    (Massachusetts General Hospital, Harvard Medical School)

  • Susanna Stinson

    (Gilead Sciences)

  • Elena Ivanova

    (Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute)

  • Amir R. Aref

    (Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute
    Xsphera Biosciences)

  • Cloud P. Paweletz

    (Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute)

  • David A. Barbie

    (Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute)

  • Debattama R. Sen

    (Massachusetts General Hospital, Harvard Medical School)

  • David E. Fisher

    (Massachusetts General Hospital and Harvard Medical School)

  • Ryan B. Corcoran

    (Massachusetts General Hospital, Harvard Medical School)

  • Nir Hacohen

    (Massachusetts General Hospital, Harvard Medical School
    Broad Institute of MIT and Harvard)

  • Peter K. Sorger

    (Harvard Medical School)

  • Keith T. Flaherty

    (Massachusetts General Hospital, Harvard Medical School)

  • Genevieve M. Boland

    (Broad Institute of MIT and Harvard
    Massachusetts General Hospital Cancer Center, Harvard Medical School)

  • Robert T. Manguso

    (Massachusetts General Hospital, Harvard Medical School
    Broad Institute of MIT and Harvard)

  • Russell W. Jenkins

    (Massachusetts General Hospital, Harvard Medical School
    Broad Institute of MIT and Harvard
    Harvard Medical School)

Abstract

Despite the success of PD-1 blockade in melanoma and other cancers, effective treatment strategies to overcome resistance to cancer immunotherapy are lacking1,2. Here we identify the innate immune kinase TANK-binding kinase 1 (TBK1)3 as a candidate immune-evasion gene in a pooled genetic screen4. Using a suite of genetic and pharmacological tools across multiple experimental model systems, we confirm a role for TBK1 as an immune-evasion gene. Targeting TBK1 enhances responses to PD-1 blockade by decreasing the cytotoxicity threshold to effector cytokines (TNF and IFNγ). TBK1 inhibition in combination with PD-1 blockade also demonstrated efficacy using patient-derived tumour models, with concordant findings in matched patient-derived organotypic tumour spheroids and matched patient-derived organoids. Tumour cells lacking TBK1 are primed to undergo RIPK- and caspase-dependent cell death in response to TNF and IFNγ in a JAK–STAT-dependent manner. Taken together, our results demonstrate that targeting TBK1 is an effective strategy to overcome resistance to cancer immunotherapy.

Suggested Citation

  • Yi Sun & Or-yam Revach & Seth Anderson & Emily A. Kessler & Clara H. Wolfe & Anne Jenney & Caitlin E. Mills & Emily J. Robitschek & Thomas G. R. Davis & Sarah Kim & Amina Fu & Xiang Ma & Jia Gwee & Pa, 2023. "Targeting TBK1 to overcome resistance to cancer immunotherapy," Nature, Nature, vol. 615(7950), pages 158-167, March.
    • Handle: RePEc:nat:nature:v:615:y:2023:i:7950:d:10.1038_s41586-023-05704-6
    DOI: 10.1038/s41586-023-05704-6
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/s41586-023-05704-6
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.
    File URL: https://libkey.io/10.1038/s41586-023-05704-6?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Jong Ho Park & Mahsa Mortaja & Heehwa G. Son & Xutu Zhao & Lauren M. Sloat & Marjan Azin & Jun Wang & Michael R. Collier & Krishna S. Tummala & Anna Mandinova & Nabeel Bardeesy & Yevgeniy R. Semenov &, 2024. "Statin prevents cancer development in chronic inflammation by blocking interleukin 33 expression," Nature Communications, Nature, vol. 15(1), pages 1-15, December.
    2. Jonas Engesser & Robin Khatri & Darius P. Schaub & Yu Zhao & Hans-Joachim Paust & Zeba Sultana & Nariaki Asada & Jan-Hendrik Riedel & Varshi Sivayoganathan & Anett Peters & Anna Kaffke & Saskia-Lariss, 2024. "Immune profiling-based targeting of pathogenic T cells with ustekinumab in ANCA-associated glomerulonephritis," Nature Communications, Nature, vol. 15(1), pages 1-12, December.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:nature:v:615:y:2023:i:7950:d:10.1038_s41586-023-05704-6. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.